Fundraising FoxCure Pharmaceutical Holding
Oxnard, US · Founded 2014 · Delaware corporation
Find your way into Cure Pharmaceutical Holding
Sign up to see every warm intro you have to Cure Pharmaceutical Holding
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cure Pharmaceutical Holding team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
CB
CHARLES BERMANNamed on SEC filing
EM
EDWARD MALISKINamed on SEC filing
MU
MARK UDELLNamed on SEC filing
WY
WILLIAM YUANNamed on SEC filing
RD
ROBERT DAVIDSONNamed on SEC filing
AE
ALAN EINSTEINNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$31.5M disclosed across 3 rounds · 2018–2020
▶$11.5MraisedNov 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$11.5MraisedNov 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert DavidsonExecutive Officer, Director
- John BellDirector
- Lauren ChungDirector
- Anya GoldinDirector
- Josh HeldDirector
- Ruben King-ShawDirector
- Gene SalkindDirector
- William YuanDirector
- Nancy DuitchDirector
- Mike RedardExecutive Officer
- Offering amount
- $11.5M
- Amount sold
- $11.5M
- Finders' fees
- $306K
- Placement agents
- Axiom Capital Management, Inc.
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$19MraisedMay 2019 · 25 investors · PharmaceuticalsRule 506(b)
▶$19MraisedMay 2019 · 25 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert DavidsonExecutive Officer, Director
- Alex KatzExecutive Officer
- Mark UdellExecutive Officer
- Alan EinsteinDirector
- William YuanDirector
- Charles BermanDirector
- Jessica RoussetExecutive Officer
- Offering amount
- $19M
- Amount sold
- $19M
- First sale
- May 2019
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1MraisedApr 2018 · 23 investors · PharmaceuticalsRule 506(b)
▶$1MraisedApr 2018 · 23 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- CHARLES BERMANDirector
- EDWARD MALISKIExecutive Officer
- MARK UDELLExecutive Officer
- WILLIAM YUANDirector
- ROBERT DAVIDSONDirector
- ALAN EINSTEINDirector
- Offering amount
- $5M
- Amount sold
- $1M
- Minimum investment
- $10K
- Sales commissions
- $100K
- Placement agents
- Alexander Capital, L.P.
- First sale
- Mar 2018
- Incorporated
- Corporation, Nevada, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Cure Pharmaceutical Holding raised?
- Cure Pharmaceutical Holding has disclosed $31.5M raised across 3 rounds.
- Where is Cure Pharmaceutical Holding headquartered?
- Cure Pharmaceutical Holding is headquartered in Oxnard, US.